Literature DB >> 25597923

Toward the development of effective transmission-blocking vaccines for malaria.

Daria Nikolaeva1, Simon J Draper, Sumi Biswas.   

Abstract

The continued global burden of malaria can in part be attributed to a complex lifecycle, with both human hosts and mosquito vectors serving as transmission reservoirs. In preclinical models of vaccine-induced immunity, antibodies to parasite sexual-stage antigens, ingested in the mosquito blood meal, can inhibit parasite survival in the insect midgut as judged by ex vivo functional studies such as the membrane feeding assay. In an era of renewed political momentum for malaria elimination and eradication campaigns, such observations have fueled support for the development and implementation of so-called transmission-blocking vaccines. While leading candidates are being evaluated using a variety of promising vaccine platforms, the field is also beginning to capitalize on global '-omics' data for the rational genome-based selection and unbiased characterization of parasite and mosquito proteins to expand the candidate list. This review covers the progress and prospects of these recent developments.

Entities:  

Keywords:  Plasmodium falciparum; genome; malaria; membrane feeding assay; transmission-blocking vaccine

Mesh:

Substances:

Year:  2015        PMID: 25597923     DOI: 10.1586/14760584.2015.993383

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  54 in total

Review 1.  Malaria vaccine clinical trials: what's on the horizon.

Authors:  Alberto Moreno; Chester Joyner
Journal:  Curr Opin Immunol       Date:  2015-07-13       Impact factor: 7.486

Review 2.  Plasmodium P47: a key gene for malaria transmission by mosquito vectors.

Authors:  Alvaro Molina-Cruz; Gaspar E Canepa; Carolina Barillas-Mury
Journal:  Curr Opin Microbiol       Date:  2017-12-08       Impact factor: 7.934

Review 3.  Determinants of Malaria Transmission at the Population Level.

Authors:  Teun Bousema; Chris Drakeley
Journal:  Cold Spring Harb Perspect Med       Date:  2017-12-01       Impact factor: 6.915

Review 4.  Vaccines to Accelerate Malaria Elimination and Eventual Eradication.

Authors:  Julie Healer; Alan F Cowman; David C Kaslow; Ashley J Birkett
Journal:  Cold Spring Harb Perspect Med       Date:  2017-09-01       Impact factor: 6.915

5.  ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum.

Authors:  Kazutoyo Miura; Bingbing Deng; Yimin Wu; Luwen Zhou; Thao P Pham; Ababacar Diouf; Chia-Kuei Wu; Shwu-Maan Lee; Jordan L Plieskatt; Merribeth J Morin; Carole A Long
Journal:  Vaccine       Date:  2019-03-05       Impact factor: 3.641

Review 6.  Immune Responses in Malaria.

Authors:  Carole A Long; Fidel Zavala
Journal:  Cold Spring Harb Perspect Med       Date:  2017-08-01       Impact factor: 6.915

7.  A Direct from Blood Reverse Transcriptase Polymerase Chain Reaction Assay for Monitoring Falciparum Malaria Parasite Transmission in Elimination Settings.

Authors:  Brian J Taylor; Kjerstin Lanke; Shanna L Banman; Isabelle Morlais; Merribeth J Morin; Teun Bousema; Sanna R Rijpma; Stephanie K Yanow
Journal:  Am J Trop Med Hyg       Date:  2017-07-19       Impact factor: 2.345

8.  Evaluation of Plasmodium vivax HAP2 as a transmission-blocking vaccine candidate.

Authors:  Yue Qiu; Yan Zhao; Fei Liu; Bo Ye; Zhenjun Zhao; Sataporn Thongpoon; Wanlapa Roobsoong; Jetsumon Sattabongkot; Liwang Cui; Qi Fan; Yaming Cao
Journal:  Vaccine       Date:  2020-02-21       Impact factor: 3.641

Review 9.  Malaria vaccines and human immune responses.

Authors:  Carole A Long; Fidel Zavala
Journal:  Curr Opin Microbiol       Date:  2016-06-02       Impact factor: 7.934

10.  Transmission-blocking activity is determined by transmission-reducing activity and number of control oocysts in Plasmodium falciparum standard membrane-feeding assay.

Authors:  Kazutoyo Miura; Bruce J Swihart; Bingbing Deng; Luwen Zhou; Thao P Pham; Ababacar Diouf; Timothy Burton; Michael P Fay; Carole A Long
Journal:  Vaccine       Date:  2016-06-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.